Tech Company Financing Transactions
Antabio Funding Round
AMR Action Fund, BNP Paribas Développement and European Innovation Council Fund participated in a $27.5 million Series B funding round for Antabio. This venture round was announced on 12/12/2023.
Transaction Overview
Company Name
Announced On
12/12/2023
Transaction Type
Venture Equity
Amount
$27,490,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the clinical development of MEM-ANT3310, a next generation antibacterial combination currently in phase 1 trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
436 Rue Pierre et Marie Curie
Labège, 31670
FR
Labège, 31670
FR
Phone
Website
Email Address
Overview
Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. The company has a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Antabio's lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Lemonnier
Browse more venture capital transactions:
Prev: 12/12/2023: True Anomaly venture capital transaction
Next: 12/12/2023: Laredo Labs venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. All VC database entries reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs